---
layout: default
title: Cupric Chloride
parent: 僅模型預測 (L5)
nav_order: 552
evidence_level: L5
indication_count: 3
---

# Cupric Chloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cupric Chloride: From Trace Element Supplementation to Primary Release Disorder of Platelets

## One-Sentence Summary

Cupric chloride (Cu²⁺) is an inorganic copper salt used primarily as a trace element supplement in parenteral nutrition formulations, with no formal approved indication on record in the US market.
The TxGNN model predicts it may be effective for **Primary Release Disorder of Platelets**, a rare inherited platelet dysfunction disorder.
Currently, **no clinical trials** and **no supporting publications** have been identified for this indication, making the evidence base entirely model-driven.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No established approved indication on record |
| Predicted New Indication | Primary Release Disorder of Platelets |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacological properties, cupric chloride is an inorganic copper(II) salt that serves as an essential trace element source. When administered (typically via parenteral nutrition), Cu²⁺ participates in enzymatic cofactor roles across multiple biological systems, including ceruloplasmin-mediated iron metabolism, superoxide dismutase activity, and mitochondrial cytochrome c oxidase function.

The model's rationale centers on the observation that copper ions may influence platelet dense granule (δ-granule) release pathways. Some in vitro studies have shown that Cu²⁺ can modulate ADP/ATP storage pools and platelet activation signals. Primary release disorder of platelets is a genetic condition (examples include Hermansky-Pudlak syndrome and Chediak-Higashi syndrome), where dense granule deficiency leads to impaired secondary hemostasis.

However, the mechanistic link remains highly speculative. The connection between copper supplementation and correction of a genetic platelet granule defect is indirect at best. The high TxGNN score most likely reflects co-occurrence of copper metabolism nodes and platelet biogenesis nodes within the knowledge graph — a graph-topological proximity — rather than a genuine pharmacological relationship. No in vivo or clinical data currently support this prediction.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is driven entirely by TxGNN model scoring (L5), with zero clinical trial registrations, zero supporting publications, and no established pharmacological mechanism linking Cu²⁺ supplementation to correction of primary platelet release disorders, which are fundamentally genetic in origin. The risk-benefit profile cannot be assessed under current evidence conditions.

**To proceed, the following is needed:**

- **Mechanism validation**: In vitro studies to confirm whether Cu²⁺ can restore dense granule secretion in relevant cell models (e.g., HPS patient-derived platelets)
- **MOA data**: Retrieval of complete DrugBank mechanism-of-action data for cupric chloride to evaluate biological plausibility more rigorously
- **Safety baseline**: Package insert warnings and contraindications must be obtained before any S1 safety screening can proceed (current status: Blocking data gap)
- **Biomarker identification**: Define a measurable platelet function endpoint (e.g., ATP secretion assay, electron microscopy for granule count) for any exploratory study design
- **Disease sub-type clarification**: Confirm which genetic subtype of primary release disorder (HPS1–11, CHS) is the intended target, as the mechanistic hypothesis differs significantly across subtypes
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

